Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19 - Summary - MDSpire

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

  • By

  • Esperanza Martín-Sánchez

  • Luis-Esteban Tamariz-Amador

  • Camila Guerrero

  • Anastasiia Zherniakova

  • Aintzane Zabaleta

  • Catarina Maia

  • Laura Blanco

  • Diego Alignani

  • Maria-Antonia Fortuño

  • Carlos Grande

  • Andrea Manubens

  • Jose-Maria Arguiñano

  • Clara Gomez

  • Ernesto Perez-Persona

  • Iñigo Olazabal

  • Itziar Oiartzabal

  • Carlos Panizo

  • Felipe Prosper

  • Jesus F. San-Miguel

  • Paula Rodriguez-Otero

  • Bruno Paiva

  • July 10, 2024

  • 0 min

Share

Objective:

To analyze immune dysfunction in multiple myeloma (MM) patients before and during COVID-19 vaccination and assess the immunogenicity of vaccines in this population, highlighting the significance of tailored vaccination strategies.

Key Findings:
  • MM patients exhibited significantly altered immune profiles with 73% of immune subsets affected compared to HCP, indicating a critical need for monitoring.
  • B-cell compartment showed reduced percentages across all subsets, while T-cell compartment alterations included a shift towards memory T cells, suggesting potential challenges in vaccine response.
  • Antigen-presenting cells were notably altered, with reduced plasmacytoid dendritic cells, which may impact overall immune response.
Interpretation:

The findings indicate profound immune dysfunction in MM patients, which may impact vaccine efficacy and necessitate tailored vaccination strategies to improve outcomes.

Limitations:
  • Small sample size of MM patients may limit generalizability, suggesting the need for larger studies.
  • Lack of long-term follow-up data on vaccine responses, which could provide insights into the durability of immune responses.
Conclusion:

Individualized vaccination strategies based on immune profiling may enhance vaccine efficacy in MM patients, who demonstrate significant immune dysfunction, underscoring the importance of personalized approaches in clinical practice.

Original Source(s)

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

  • by Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, Anastasiia Zherniakova, Aintzane Zabaleta, Catarina Maia, Laura Blanco, Diego Alignani, Maria-Antonia Fortuño, Carlos Grande, Andrea Manubens, Jose-Maria Arguiñano, Clara Gomez, Ernesto Perez-Persona, Iñigo Olazabal, Itziar Oiartzabal, Carlos Panizo, Felipe Prosper, Jesus F. San-Miguel, Paula Rodriguez-Otero, Bruno Paiva

  • July 10, 2024

Related Content

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

Equity and representation in oncology clinical evidence for FDA-approved treatments and the impact of COVID-19

Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study